Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing

被引:304
作者
Li, Jin [1 ,2 ,3 ]
Wang, Lilin [1 ,2 ,3 ]
Mamon, Harvey [1 ,2 ,3 ]
Kulke, Matthew H. [4 ]
Berbeco, Ross [1 ,2 ,3 ]
Makrigiorgos, G. Mike [1 ,2 ,3 ]
机构
[1] Harvard Univ, Sch Med, Div Genom Stabil & DNA Repair, Dept Radiat Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Div Phys, Dept Radiat Oncol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Div Radiat Therapy, Dept Radiat Oncol, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
关键词
D O I
10.1038/nm1708
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
PCR is widely employed as the initial DNA amplification step for genetic testing. However, a key limitation of PCR-based methods is the inability to selectively amplify low levels of mutations in a wild-type background. As a result, downstream assays are limited in their ability to identify subtle genetic changes that can have a profound impact in clinical decision-making and outcome. Here we describe co-amplification at lower denaturation temperature PCR ( COLD-PCR), a novel form of PCR that amplifies minority alleles selectively from mixtures of wild-type and mutation-containing sequences irrespective of the mutation type or position on the sequence. We replaced regular PCR with COLD-PCR before sequencing or genotyping assays to improve mutation detection sensitivity by up to 100-fold and identified new mutations in the genes encoding p53, KRAS and epidermal growth factor in heterogeneous cancer samples that had been missed by the currently used methods. For clinically relevant microdeletions, COLD-PCR enabled exclusive amplification and isolation of the mutants. COLD-PCR will transform the capabilities of PCR-based genetic testing, including applications in cancer, infectious diseases and prenatal identification of fetal alleles in maternal blood.
引用
收藏
页码:579 / 584
页数:6
相关论文
共 27 条
[1]   Gene promoter methylation in plasma and sputum increases with lung cancer risk [J].
Belinsky, SA ;
Klinge, DM ;
Dekker, JD ;
Smith, MW ;
Bocklage, TJ ;
Gilliland, FD ;
Crowell, RE ;
Karp, DD ;
Stidley, CA ;
Picchi, MA .
CLINICAL CANCER RESEARCH, 2005, 11 (18) :6505-6511
[2]   Detection and quantification of mutations in the plasma of patients with colorectal tumors [J].
Diehl, F ;
Li, M ;
Dressman, D ;
He, YP ;
Shen, D ;
Szabo, S ;
Diaz, LA ;
Goodman, SN ;
David, KA ;
Juhl, H ;
Kinzler, KW ;
Vogelstein, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (45) :16368-16373
[3]   Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].
Eberhard, DA ;
Johnson, BE ;
Amler, LC ;
Goddard, AD ;
Heldens, SL ;
Herbst, RS ;
Ince, WL ;
Jänne, PA ;
Januario, T ;
Johnson, DH ;
Klein, P ;
Miller, VA ;
Ostland, MA ;
Ramies, DA ;
Sebisanovic, D ;
Stinson, JA ;
Zhang, YR ;
Seshagiri, S ;
Hillan, KJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909
[4]   Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer [J].
Engelman, Jeffrey A. ;
Mukohara, Toru ;
Zejnullahu, Kreshnik ;
Lifshits, Eugene ;
Borras, Ana M. ;
Gale, Christopher-Michael ;
Naumov, George N. ;
Yeap, Beow Y. ;
Jarrell, Emily ;
Sun, Jason ;
Tracy, Sean ;
Zhao, Xiaojun ;
Heymach, John V. ;
Johnson, Bruce E. ;
Cantley, Lewis C. ;
Janne, Pasi A. .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (10) :2695-2706
[5]  
Fuery CJ, 2000, CLIN CHEM, V46, P620
[6]   Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients:: Follow-up study and prognostic significance [J].
Gonzalez, R ;
Silva, JM ;
Sanchez, A ;
Dominguez, G ;
Garcia, JM ;
Chen, XQ ;
Stroun, M ;
Provencio, M ;
España, P ;
Anker, P ;
Bonilla, F .
ANNALS OF ONCOLOGY, 2000, 11 (09) :1097-1104
[7]   Patterns of somatic mutation in human cancer genomes [J].
Greenman, Christopher ;
Stephens, Philip ;
Smith, Raffaella ;
Dalgliesh, Gillian L. ;
Hunter, Christopher ;
Bignell, Graham ;
Davies, Helen ;
Teague, Jon ;
Butler, Adam ;
Edkins, Sarah ;
O'Meara, Sarah ;
Vastrik, Imre ;
Schmidt, Esther E. ;
Avis, Tim ;
Barthorpe, Syd ;
Bhamra, Gurpreet ;
Buck, Gemma ;
Choudhury, Bhudipa ;
Clements, Jody ;
Cole, Jennifer ;
Dicks, Ed ;
Forbes, Simon ;
Gray, Kris ;
Halliday, Kelly ;
Harrison, Rachel ;
Hills, Katy ;
Hinton, Jon ;
Jenkinson, Andy ;
Jones, David ;
Menzies, Andy ;
Mironenko, Tatiana ;
Perry, Janet ;
Raine, Keiran ;
Richardson, Dave ;
Shepherd, Rebecca ;
Small, Alexandra ;
Tofts, Calli ;
Varian, Jennifer ;
Webb, Tony ;
West, Sofie ;
Widaa, Sara ;
Yates, Andy ;
Cahill, Daniel P. ;
Louis, David N. ;
Goldstraw, Peter ;
Nicholson, Andrew G. ;
Brasseur, Francis ;
Looijenga, Leendert ;
Weber, Barbara L. ;
Chiew, Yoke-Eng .
NATURE, 2007, 446 (7132) :153-158
[8]   DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations [J].
Hoffmann, Christian ;
Minkah, Nana ;
Leipzig, Jeremy ;
Wang, Gary ;
Arens, Max Q. ;
Tebas, Pablo ;
Bushman, Frederic D. .
NUCLEIC ACIDS RESEARCH, 2007, 35 (13)
[9]   Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer [J].
Huang, C ;
Taki, T ;
Adachi, M ;
Konishi, T ;
Higashiyama, M ;
Miyake, M .
ONCOGENE, 1998, 16 (19) :2469-2477
[10]  
Huang CL, 1998, INT J ONCOL, V12, P553